Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter’s Chinese API Supplier Cited For “Objectionable Practices;” Remaining Heparin Vials Recalled

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA has issued a Form 483 to Changzhou SPL, Baxter Healthcare's heparin API supplier, after inspecting the Changzhou City plant, FDA announced Feb. 28 during an update of the agency's ongoing investigation of Baxter's heparin products

You may also be interested in...



Heparin Alert Hits Device Makers

U.S. FDA sent a letter April 8 to 82 medical device manufacturers urging them to test any products containing heparin for contamination

Heparin Alert Hits Device Makers

U.S. FDA sent a letter April 8 to 82 medical device manufacturers urging them to test any products containing heparin for contamination

U.S. FDA Triples Estimate On Deaths Following Allergic Reaction To Blood Thinner Heparin

BEIJING - U.S. FDA last week issued a sharply higher estimate on the number of deaths that have occurred in patients who suffered allergic reactions to the blood thinner heparin

Related Content

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel